[DOI] [PMC free article] [PubMed] [Google Scholar] 4.Bauer A.Z., Swan S.H., Kriebel D., Liew Z., Taylor H.S., Bornehag C., Andrade A.M., Olsen J., Jensen R.H., Mitchell R.T., et al
The FDA, recognizing the potential, has initiated fast-tracking considerations for its approval as a weight loss adjunct
Ultimately, the duration of GLP-1RA treatment seems to be the factor that explains the heterogeneity of the clinical studies involving GLP-1RA
@LillyPad #medtwitter #endotwitter pubmed.ncbi.nlm.nih.gov/35985340/ #retatrutide is a novel triple agonist peptide at the glucagon receptor, GIP receptor, and GLP-1 receptor
The ECAR profile (Fig
The FDA has only approved Rybelsus to: Improve blood sugar control in adults with type 2 diabetes, along with diet and exercise Reduce the risk of major cardiovascular events like heart attack or stroke in adults with type 2 diabetes Research on Rybelsus and weight loss in non-diabetic patients Most of the research on Rybelsus for weight loss has been conducted in people with type 2 diabetes, since its a diabetes medication
